サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1591395

抗生物質・抗真菌剤市場規模および予測、世界および地域シェア、動向、成長機会分析レポート：薬剤クラス別、適応症別、投与経路別、流通チャネル別、地域別

Antibiotics and Antimycotics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Route of Administration, Distribution Channel, and Geography

出版日
ページ情報
英文 203 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
抗生物質・抗真菌剤市場規模および予測、世界および地域シェア、動向、成長機会分析レポート：薬剤クラス別、適応症別、投与経路別、流通チャネル別、地域別
出版日: 2024年11月04日
発行: The Insight Partners
ページ情報: 英文 203 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗生物質・抗真菌剤市場は、2023年の612億米ドルから成長し、2031年には915億4,000万米ドルに達すると予測されており、2023年から2031年のCAGRは5.2%と予測されています。抗生物質と抗真菌剤市場の成長は、高齢者人口の増加、歯科疾患の負担増、審美歯科の需要急増に起因しています。

抗生物質と抗真菌剤は、さまざまな種類の病原体を標的とする抗菌剤です。抗生物質はさらに、細菌を死滅させる殺菌性抗生物質（ペニシリン系、セファロスポリン系）と細菌の増殖を抑制する静菌性抗生物質（テトラサイクリン系、マクロライド系）に分類されます。抗生物質は細菌感染症の治療に広く使用されていますが、抗生物質耐性株の増加により、その有効性が課題となっています。抗真菌剤は、真菌感染症に特化した薬です。抗真菌剤は、真菌の細胞構造や代謝の様々な側面を標的とすることで効果を発揮します。一般的なクラスの抗真菌剤には、アゾール系（フルコナゾール）、ポリエン系（アムホテリシンB）、エキノカンディン系（カスポファンギン）などがあります。抗真菌剤は、カンジダ症やアスペルギルス症など、真菌によって引き起こされる疾患の治療に不可欠です。

北米の抗生物質・抗真菌剤市場は米国、カナダ、メキシコに区分されます。同市場は主に、細菌および真菌感染症の有病率の上昇、新興国市場のヘルスケア・インフラの存在、こうした感染症の治療に幅広い抗生物質および抗真菌剤が利用可能であることが要因となっています。さらに、製品の上市、承認、その他大手企業による戦略的イニシアチブの増加は、予測期間中に市場成長の機会を創出すると期待されています。

北米では、米国が抗生物質・抗真菌剤の最大市場です。米国の抗生物質・抗真菌剤市場の成長を牽引しているのは、真菌・細菌感染症の有病率の増加と、効果的な治療オプションに対するニーズの高まりです。肺炎は米国で最も一般的な呼吸器感染症です。Verywell Health Journal 2024のレポートによると、米国では毎年～150万人の成人が肺炎と診断され、そのうち約100万人が入院し、5万人が肺炎や関連合併症で死亡しています。アモキシシリンとアジスロマイシンは、米国で細菌感染症の治療のために外来で最もよく処方される抗生物質です。また、医薬品研究や技術の進歩に伴い、新しい抗生物質や抗真菌剤の開発が勢いを増しており、抗生物質耐性に対する懸念の高まりや革新的な治療法の必要性に応えています。さらに、抗菌薬スチュワードシップ・プログラムの重要性に対する認識の高まりは、抗生物質の処方に対するより慎重なアプローチにつながり、標的療法や併用療法へのシフトを促しています。これは特に病院環境において顕著であり、院内感染の増加により強力な抗菌薬の使用が必要となっています。

主要企業は、製品上市、製品承認、提携などの戦略的イニシアチブをとっており、予測期間中の市場成長を支えるものと期待されます。例えば、2024年4月、US Food and Drug Administration（FDA）は、Zevtera（注射用セフトビプロレ・メドカリル・ナトリウム）を、右側感染性心内膜炎を含む黄色ブドウ球菌血流感染症（SAB）に罹患している成人および急性細菌性皮膚・皮膚構造感染症（ABSSSI）に罹患している成人の治療薬として承認しました。さらに、US Food and Drug Administrationは2023年3月、カンジダ血症および侵襲性カンジダ症の治療薬としてREZZAYO（注射用レザファンギン）を承認しました。

製品開発と治療デリバリー・アプローチにおける技術の進歩

製薬業界は、新しい抗生物質の開発にディープラーニング、人工知能（AI）、機械学習などのインテリジェント技術を取り入れることを重視しています。研究者は、新たな活性化合物を同定するためのツールやプラットフォームの確立に取り組んでいます。新しい抗生物質の発見において新規技術の能力を活用することで、抗生物質や抗真菌剤の開発・承認プロセスの全体的な流れが変わると期待されています。

グラム陰性菌に対する抗生物質の開発は研究者にとって大きな課題であり、多くの薬剤がまだ開発段階にあります。これらの細菌のエンベロープは、栄養特異的タンパク質チャネル（ポリン）により透過性が制限されており、膜を介した非必須分子（抗生物質を含む）の移動が制限されています。細胞膜透過性をめぐる困難を考慮し、研究者は、ポリンの分析に基づいて潜在的な薬剤分子を同定するのに役立つ新しい計算抗生物質スクリーニング・プラットフォーム（CLASP）を開発しました。粗視化（CG）解像度、高度なサンプリング技術、並列コンピューティング環境などの利点が、CLASPの性能を最大限に引き出します。このプラットフォームは、研究対象の潜在的な薬剤分子について、熱力学的および動力学的な完全な結果を数時間で提供します。また、浸透性の高い抗生物質を発見するための構造-物性相関をもたらす低分子ライブラリーの理解や同定にも役立ちます。

患者の遺伝子プロファイルや大規模集団に共通する耐性パターンに基づいて抗生物質治療を調整する精密医療への傾倒が高まっています。このような革命は、副作用を最小限に抑え、耐性菌の発生を抑制しながら、薬剤の機能性を向上させると思われます。ファージ療法は、従来の微生物治療とバクテリオファージを組み合わせることで、抗生物質耐性の病原体を標的にし、破壊する可能性のある、もうひとつの新しいアプローチとして登場しました。CRISPRのような遺伝子編集技術における最近の有望な進歩は、ファージ療法の可能性をさらに高める力を持っています。このように、薬剤開発や治療デリバリーアプローチにおける技術進歩は、抗生物質・抗真菌剤市場の成長に今後数年間、新たな成長動向をもたらすと予想されます。

抗生物質・抗真菌剤市場：競合情勢と主な発展

Pfizer Inc、Novartis AG、Sanofi SA、F. Hoffmann-La Roche Ltd、Merck & Co Inc、GSK Plc、Johnson & Johnson、Cipla Ltd、Bayer AG、AbbVie Inc、Astellas Pharma Incなどが抗生物質・抗真菌剤市場の主要企業です。

US Food and Drug Administration、National Institute of Health、United Nations International Children's Emergency Fund (UNICEF)、World Health Organization (WHO)、National Notifiable Diseases Surveillance Systemなどは、抗生物質・抗真菌剤市場レポートを作成する際に参照した一次および二次情報の一つです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 2次調査
  • 1次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の作成
    • データの三角測量
    • 国レベルのデータ

第4章 抗生物質・抗真菌剤の市場情勢

  • PEST分析

第5章 抗生物質・抗真菌剤市場：主要市場力学

  • 抗生物質・抗真菌剤市場- 主な市場力学
  • 市場促進要因
    • 感染症罹患率の増加
    • 真菌感染症に対する意識の高まり
  • 市場抑制要因
    • 抗菌薬耐性、経済的障壁、広範な規制プロセス
  • 市場機会
    • 継続的な資金調達と研究開発イニシアティブ
  • 今後の動向
    • 製品開発と治療提供アプローチにおける技術進歩
  • 促進要因と阻害要因の影響

第6章 抗生物質・抗真菌剤市場：世界市場分析

  • 抗生物質・抗真菌剤市場の売上高、2021年～2031年
  • 抗生物質・抗真菌剤市場の予測分析

第7章 抗生物質・抗真菌剤市場の分析：薬剤クラス別

  • ペニシリン
  • セファロスポリン
  • カルバペネム系抗生物質
  • マクロライド
  • アミノグリコシド
  • キノロン系抗菌薬
  • スルホンアミド系
  • テトラサイクリン系抗生物質
  • アゾール系
  • その他

第8章 抗生物質・抗真菌剤市場分析：適応症別

  • 皮膚感染症
  • 呼吸器感染症
  • 尿路感染症（UTI）
  • 敗血症
  • 耳感染症
  • 消化器感染症
  • その他

第9章 抗生物質・抗真菌剤市場分析：投与経路別

  • 経口剤
  • 局所投与
  • その他

第10章 抗生物質・抗真菌剤市場分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 抗生物質・抗真菌剤市場：地域別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • 英国
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • アジア太平洋地域のその他諸国
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • その他中東とアフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第12章 抗生物質・抗真菌剤市場- 業界情勢

  • 抗生物質・抗真菌剤市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第13章 企業プロファイル

  • Pfizer Inc
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • GSK Plc
  • Johnson & Johnson
  • Cipla Ltd
  • Bayer AG
  • AbbVie Inc
  • Astellas Pharma Inc

第14章 付録

図表

List Of Tables

  • Table 1. Antibiotics and Antimycotics Market Segmentation
  • Table 2. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 4. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 8. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 12. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 15. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 16. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 17. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 18. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 19. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 20. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 21. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 23. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 24. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 25. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 27. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 28. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 29. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 30. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 31. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 32. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 33. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 34. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 35. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 36. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 37. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 38. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 39. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 40. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 41. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 42. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 43. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 44. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 45. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 46. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 47. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 48. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 49. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 50. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 51. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 52. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 53. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 54. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 55. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 56. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 57. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 58. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 59. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 60. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 61. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 62. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 63. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 64. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 65. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 66. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 67. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 68. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 69. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 70. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 71. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 72. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 73. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 74. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 75. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 76. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 77. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 78. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 79. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 80. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 81. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 82. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 83. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 84. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 85. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 86. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 87. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 88. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 89. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 90. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 91. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 92. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 93. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 94. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 95. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 96. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 97. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 98. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 99. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 100. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 101. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 102. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 103. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 104. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 105. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 106. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 107. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 108. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 109. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 110. Recent Organic Growth Strategies in Antibiotics and Antimycotics Market
  • Table 111. Recent Inorganic Growth Strategies in the Antibiotics and Antimycotics Market
  • Table 112. Glossary of Terms, Antibiotics and Antimycotics Market

List Of Figures

  • Figure 1. Antibiotics and Antimycotics Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Antibiotics and Antimycotics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Penicillin: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cephalosporines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Carbapenems: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Macrolides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Aminoglycosides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Quinolones: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Sulfonamides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Tetracyclines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Azoles: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Antibiotics and Antimycotics Market Share (%) - by Indication (2023 and 2031)
  • Figure 18. Skin Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Respiratory Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Urinary Tract Infections (UTI): Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Septicemia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Ear Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Gastrointestinal Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Antibiotics and Antimycotics Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 26. Oral: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Topical: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. Antibiotics and Antimycotics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 30. Hospital Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. Retail Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Online Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. North America: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 35. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Europe: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 40. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Asia Pacific: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 48. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 56. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 60. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. South and Central America: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 62. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 64. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 65. Growth Strategies in Antibiotics and Antimycotics Market
目次
Product Code: TIPRE00021878

The global antibiotics and antimycotics market is anticipated to grow from US$ 61.20 billion in 2023 and is projected to reach US$ 91.54 billion by 2031; it is expected to register a CAGR of 5.2% during 2023-2031. The antibiotics and antimycotics market growth is attributed to the increasing geriatric population, the growing burden of dental diseases, and the surging demand for cosmetic dentistry.

Antibiotics and antimycotics are antimicrobial agents targeting different types of pathogens. Antibiotics are further classified into bactericidal antibiotics, which kill bacteria (penicillins and cephalosporins), and bacteriostatic antibiotics, which inhibit bacterial growth (tetracyclines and macrolides). Antibiotics are widely used to treat bacterial infections, but their effectiveness is challenged by the rise of antibiotic-resistant strains. Antimycotics are specifically designed to combat fungal infections. They work by targeting various aspects of fungal cell structure or metabolism. Common classes of antimycotics include azoles (fluconazole), polyenes (amphotericin B), and echinocandins (caspofungin). Antimycotics are essential in treating conditions caused by fungi, such as candidiasis and aspergillosis.

The North America antibiotics and antimycotics market is segmented into the US, Canada, and Mexico. The market is mainly driven by the rising prevalence of bacterial and fungal infections, the presence of developed healthcare infrastructure, and the availability of a wide range of antibiotics and antimycotics for the treatment of such infections. Additionally, the rise in product launches, approvals, and other strategic initiatives by major players is expected to create opportunities for the market growth during the forecast period.

In North America, the US is the largest market for antibiotics and antimycotics. The US antibiotics and antimycotics market growth is driven by the increasing prevalence of fungal and bacterial infections and the growing need for effective treatment options. Pneumonia is the most common respiratory infection in the US. According to Verywell Health Journal 2024 report, every year, ~1.5 million adults in the US are diagnosed with pneumonia; of which around 1 million are admitted to hospitals while 50,000 people die due to pneumonia or related complications. Amoxicillin and azithromycin are the most commonly used antibiotics prescribed in the US in outpatient settings for the treatment of bacterial infections. In addition, with ongoing advancements in pharmaceutical research and technology, the development of new antibiotics and antifungal agents has gained momentum, responding to the growing concerns about antibiotic resistance and the need for innovative therapies. Moreover, the growing awareness about the importance of antimicrobial stewardship programs has led to a more cautious approach to antibiotic prescription, prompting a shift toward targeted therapies and combination treatments. This is particularly evident in hospital settings, where the growing incidence of hospital-acquired infections necessitates the use of potent antimicrobials.

Key players are taking strategic initiatives such as product launches, product approvals, and collaborations, which are expected to support the market growth during the forecast period. For instance, in April 2024, the US Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults suffering from Staphylococcus aureus bloodstream infections (SAB), including those with right-sided infective endocarditis and adults suffering from acute bacterial skin and skin structure infections (ABSSSI). Additionally, in March 2023, The US FDA approved REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis.

Technological Advancements in Product Development and Treatment Delivery Approaches

The pharmaceutical industry emphasizes incorporating intelligent technologies such as deep learning, artificial intelligence (AI), and machine learning in the development of new antibiotics. Researchers are working to establish tools and platforms for identifying new active compounds. Harnessing the capabilities of novel technologies in new antibiotic discoveries is expected to change the overall course of antibiotic and antimycotic development and approval processes.

Developing antibiotics for Gram-negative bacteria poses a significant challenge to researchers, and many drugs are still in the development phases. Limited permeability across the envelope of these bacteria due to nutrient-specific protein channels (porins) restricts the movement of non-essential molecules (including antibiotics) across membranes. Considering the difficulties around cell membrane permeability, researchers have developed a new Computational Antibiotic Screening Platform (CLASP) that helps identify potential drug molecules based on the analysis of porins. Advantages such as coarse grain (CG) resolution, advanced sampling techniques, and a parallel computing environment maximize the performance of CLASPs. The platform provides complete thermodynamic and kinetic results for a potential drug molecule under study in a few hours. It also helps understand or identify small molecule libraries that yield structure-property relationships to discover antibiotics with high permeability.

There is a rising inclination toward precision medicine approaches that involve adjusting antibiotic treatments based on patients' genetic profiles and resistance patterns that are common among large populations. Such a revolution would improve drugs' functionality while ensuring minimal adverse effects and curbing the development of resistance. Phage therapy has emerged as another novel approach that involves a potential combination of traditional microbial treatments with bacteriophages to target and destroy antibiotic-resistant pathogens. Promising recent advancements in gene-editing technologies, such as CRISPR, has the ability to further enhance the prospects of phage therapy. Thus, technological advancements in drug development and treatment delivery approaches are expected to bring new growth trends in the antibiotics and antimycotics market growth in the coming years.

Antibiotics and Antimycotics Market: Competitive Landscape and Key Developments

Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. are among the key companies operating in the antibiotics and antimycotics market.

The US Food and Drug Administration, National Institute of Health, United Nations International Children's Emergency Fund (UNICEF), World Health Organization (WHO), National Notifiable Diseases Surveillance System are among the primary and secondary sources referred to while preparing the antibiotics and antimycotics market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Antibiotics and Antimycotics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Antibiotics and Antimycotics Market - Key Market Dynamics

  • 5.1 Antibiotics and Antimycotics Market - Key Market Dynamics
  • 5.2 Market Drivers:
    • 5.2.1 Increasing Prevalence of Infectious Diseases
    • 5.2.2 Growing Awareness About Fungal Infections
  • 5.3 Market Restraints
    • 5.3.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
  • 5.4 Market Opportunities
    • 5.4.1 Ongoing Funding and Research & Development Initiatives
  • 5.5 Future Trends
    • 5.5.1 Technological Advancements in Product Development and Treatment Delivery Approaches
  • 5.6 Impact of Drivers and Restraints:

6. Antibiotics and Antimycotics Market - Global Market Analysis

  • 6.1 Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • 6.2 Antibiotics and Antimycotics Market Forecast Analysis

7. Antibiotics and Antimycotics Market Analysis - by Drug Class

  • 7.1 Penicillin
    • 7.1.1 Overview
    • 7.1.2 Penicillin: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Cephalosporines
    • 7.2.1 Overview
    • 7.2.2 Cephalosporines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Carbapenems
    • 7.3.1 Overview
    • 7.3.2 Carbapenems: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Macrolides
    • 7.4.1 Overview
    • 7.4.2 Macrolides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Aminoglycosides
    • 7.5.1 Overview
    • 7.5.2 Aminoglycosides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Quinolones
    • 7.6.1 Overview
    • 7.6.2 Quinolones: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Sulfonamides
    • 7.7.1 Overview
    • 7.7.2 Sulfonamides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.8 Tetracyclines
    • 7.8.1 Overview
    • 7.8.2 Tetracyclines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.9 Azoles
    • 7.9.1 Overview
    • 7.9.2 Azoles: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.10 Others
    • 7.10.1 Overview
    • 7.10.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibiotics and Antimycotics Market Analysis - by Indication

  • 8.1 Skin Infections
    • 8.1.1 Overview
    • 8.1.2 Skin Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Respiratory Infections
    • 8.2.1 Overview
    • 8.2.2 Respiratory Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Urinary Tract Infections (UTI)
    • 8.3.1 Overview
    • 8.3.2 Urinary Tract Infections (UTI): Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Septicemia
    • 8.4.1 Overview
    • 8.4.2 Septicemia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Ear Infections
    • 8.5.1 Overview
    • 8.5.2 Ear Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Gastrointestinal Infections
    • 8.6.1 Overview
    • 8.6.2 Gastrointestinal Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibiotics and Antimycotics Market Analysis - by Route Of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Topical
    • 9.2.1 Overview
    • 9.2.2 Topical: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibiotics and Antimycotics Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Retail Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Retail Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibiotics and Antimycotics Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Antibiotics and Antimycotics Market Overview
    • 11.1.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.2.1 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.1.2.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.1.2.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.1.2.4 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.1.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.1.3.1 United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.1.1 United States: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.1.2 United States: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.1.3 United States: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.1.4 United States: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.1.3.2 Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.2.1 Canada: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.2.2 Canada: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.2.3 Canada: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.2.4 Canada: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.1.3.3 Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.3.1 Mexico: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.3.2 Mexico: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.3.3 Mexico: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.3.4 Mexico: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Europe Antibiotics and Antimycotics Market Overview
    • 11.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.2.1 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.2.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.2.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.2.2.4 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.2.3.1 Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.1.1 Germany: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.1.2 Germany: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.1.3 Germany: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.1.4 Germany: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.2 France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.2.1 France: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.2.2 France: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.2.3 France: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.2.4 France: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.3 Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.3.1 Spain: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.3.2 Spain: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.3.3 Spain: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.3.4 Spain: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.4 Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.4.1 Italy: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.4.2 Italy: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.4.3 Italy: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.4.4 Italy: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.5 United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.5.1 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.5.2 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.5.3 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.5.4 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.6 Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.6.1 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.6.2 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.6.3 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.6.4 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Antibiotics and Antimycotics Market Overview
    • 11.3.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.2.1 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.3.2.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.3.2.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.3.2.4 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.3.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.1 China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.1.1 China: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.1.2 China: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.1.3 China: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.1.4 China: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.2 Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.1 Japan: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.2.2 Japan: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.2.3 Japan: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.2.4 Japan: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.3 India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.1 India: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.3.2 India: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.3.3 India: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.3.4 India: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.4 Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.1 Australia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.4.2 Australia: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.4.3 Australia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.4.4 Australia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.5 South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.1 South Korea: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.5.2 South Korea: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.5.3 South Korea: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.5.4 South Korea: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.6 Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.1 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.6.2 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.6.3 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.6.4 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.4 Middle East and Africa
    • 11.4.1 Middle East and Africa Antibiotics and Antimycotics Market Overview
    • 11.4.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.4.2.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.4.2.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.4.2.4 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.4.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.1.1 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.1.2 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.1.3 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.1.4 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.2 South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 South Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.2.2 South Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.2.3 South Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.2.4 South Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.3 United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.3.2 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.3.3 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.3.4 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.4.2 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.4.3 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.4.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.5 South and Central America
    • 11.5.1 South and Central America Antibiotics and Antimycotics Market Overview
    • 11.5.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.5.2.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.5.2.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.5.2.4 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.5.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.1.1 Brazil: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.1.2 Brazil: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.1.3 Brazil: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.1.4 Brazil: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.5.3.2 Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 Argentina: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.2.2 Argentina: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.2.3 Argentina: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.2.4 Argentina: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.5.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.3.2 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.3.4 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel

12. Antibiotics and Antimycotics Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Antibiotics and Antimycotics Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Pfizer Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sanofi SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 F. Hoffmann-La Roche Ltd
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Merck & Co Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 GSK Plc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Johnson & Johnson
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Cipla Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bayer AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 AbbVie Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Astellas Pharma Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms